Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate Life Science Investing
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909Â and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting Life Science Investing
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates Life Science Investing
Quantum-Si Announces First Customer Samples Tested on the Proteus Prototype System Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
